The project seeks to support federal policymakers in advancing drug pricing policy in 2019 and 2020 and to provide continuing education to lawmakers about the key drivers of U.S. pharmaceutical spending. It will provide: analysis and commentary on policy proposals and activity on drug pricing; technical assistance on policy solutions under consideration and education on larger issues in drug pricing; and an update of a previously published Fund report with new data, including pricing trends and updated solutions to inform debate leading into the 2020 election cycle.
Addressing High Prescription Drug Prices: Advancing Policy Solutions and Looking Ahead to Solve Complicated Problems
Grantee Organization
Waxman Consulting, Inc.
Principal Investigator
William Corr, J.D.
Term
8/1/19 - 7/31/20
Award Amount
$315,250
Approval Year
Related Program
Controlling Health Care Costs
Grantee Organization
Waxman Consulting, Inc.
Principal Investigator
William Corr, J.D.
Term
8/1/19 - 7/31/20
Award Amount
$315,250
Approval Year
Related Program
Controlling Health Care Costs